EPS for UroGen Pharma Ltd. (URGN) Expected At $-0.91

August 12, 2018 - By Benjamin Allen

Analysts expect UroGen Pharma Ltd. (NASDAQ:URGN) to report $-0.91 EPS on August, 13.They anticipate $0.21 EPS change or 30.00 % from last quarter’s $-0.7 EPS. After having $-0.88 EPS previously, UroGen Pharma Ltd.’s analysts see 3.41 % EPS growth. The stock increased 3.49% or $1.58 during the last trading session, reaching $46.88. About 44,612 shares traded. UroGen Pharma Ltd. (NASDAQ:URGN) has risen 228.14% since August 12, 2017 and is uptrending. It has outperformed by 215.57% the S&P500.

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company has market cap of $725.42 million. The Company’s lead product candidates, MitoGel and VesiGel are formulations of the chemotherapy drug Mitomycin C, a generic drug which is currently used off-label for urothelial cancer treatment only in a water formulation as an adjuvant, or supplemental post-surgery, therapy. It currently has negative earnings. The firm is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer.

More news for UroGen Pharma Ltd. (NASDAQ:URGN) were recently published by: Nasdaq.com, which released: “UroGen Pharma to Report Second Quarter 2018 Financial Results on Tuesday, August 14, 2018” on August 07, 2018. Globenewswire.com‘s article titled: “UroGen Pharma Appoints Peter P. Pfreundschuh as Chief Financial Officer” and published on August 08, 2018 is yet another important article.

UroGen Pharma Ltd. (NASDAQ:URGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.